Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

(2021) Susan E. Dorman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis

(2020) Andreas H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of Delpazolid for the Treatment of Tuberculosis

(2020) Young Lag Cho et al.   Applied Sciences-Basel

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

(2019) Andrew J. Nunn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic

(2018) Jung Sunwoo et al.   Drug Design Development and Therapy

Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371

(2018) Yong-Soon Cho et al.   CLINICAL THERAPEUTICS

Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers

(2018) Yong-Soon Cho et al.   CLINICAL THERAPEUTICS

Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis

(2016) Jennifer J. Furin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis

(2016) Akosua Adom Agyeman et al.   Annals of Clinical Microbiology and Antimicrobials

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

(2015) Rokeya Tasneen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones

(2015) Antonios Douros et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

(2015) Rodney Dawson et al.   LANCET

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

(2015) Ashley N. Brown et al.   mBio

Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis

(2014) Robert S. Wallis et al.   PLoS One

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

(2011) A. H. Diacon et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

In Vitro and In Vivo Activities of LCB01-0371, a New Oxazolidinone

(2010) J.-W. Jeong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY